2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2040

Opportunistic Infections in Patients Treated with Biologic Drug Therapy
Abstract Number: 2146

Optimal Hand Position for Reliable Volumetric Joint Space Width Measurements Using High-Resolution Peripheral Quantitative Computed Tomography
Abstract Number: 585

Optimism Levels Are Moderate and Similar in Patients with Axial Spondyloarthritis and Chronic Low Back Pain, and Are Related to Mental Quality of Life but Not Physical Quality of Life. a Cross Sectional Study of 277 Patients
Abstract Number: 2699

Optimizing Scleroderma Centers of Excellence: Perspectives from Patients and Scleroderma (SSc) Experts
Abstract Number: 1204

Oral Administration of Nano-Emulsion Curcumin in Mice Suppresses Inflammatory-Induced NFkB Signaling and Macrophage Migration
Abstract Number: 2278

Orbital Pseudotumor As the Presenting Symptom of Pediatric ANCA-Associated Vasculitis
Abstract Number: 1190

Osteoarthritis-like Changes Are Present in the Tibia and Femur 1 Year Following ACL Reconstruction
Abstract Number: 695

Osteonecrosis in Patients with Systemic Lupus Erythematosus: Risk Factors and Clinical Outcome
Abstract Number: 699

Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes
Abstract Number: 1389

Osteophytes Increase the Ambiguity of Clinical Evaluation of Joint Swelling in Rheumatoid Arthritis
Abstract Number: 2004

Osteoporosis Screening and Fracture Risk Assessment Tool Usage Among House Staff
Abstract Number: 48

Osteoporotic Women at High Risk for Fractures Despite Two Years of Oral Bisphosphonate Therapy: Analysis Using the Canadian Multicentre Osteoporosis Study
Abstract Number: 2459

Osteoprotegerin CGA Haplotype Protection Against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis
Abstract Number: 2461

Osteprotegerin Concentrations Are Independently Related to Established Cardiovascular Disease in Rheumatoid Arthritis
Abstract Number: 1773

Otolaryngologic Lesions Are Not Rare and Closely Related with Pachymeningitis and Cranial Neuropathy in MPO-ANCA Associated Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].